Patents Examined by Bridget E. Bunner
  • Patent number: 10314882
    Abstract: The present disclosure provides methods and uses of Tie2 agonists alone or in combination with antiviral agents. In particular, the present disclosure provides methods and uses for treating influenza, treating a bacterial superinfection associated with influenza and decreasing lung endothelial leakage. The disclosure also provides compositions comprising (a) a Tie2 agonist and (b) an antiviral agent and methods and uses thereof.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: June 11, 2019
    Assignees: Sunnybrook Research Institute, Unity Health Toronto
    Inventors: Daniel Dumont, Paul Van Slyke, Warren Lee
  • Patent number: 10316105
    Abstract: The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis. In certain embodiments, pairs of activating Tie-2 antibodies showed an additive effect on the treatment of influenza infection when combined with anti-influenza HA. In other embodiments, prophylactic administration pairs of activating Tie2 antibodies delayed death and improved survival in a lethal model of E. coli intoxication (sepsis) over isotype/untreated controls.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: June 11, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Gavin Thurston
  • Patent number: 10316104
    Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: June 11, 2019
    Assignee: ROCHE GLYCART AG
    Inventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
  • Patent number: 10316098
    Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: June 11, 2019
    Assignee: Stemline Therapeutics, Inc.
    Inventor: Ivan Bergstein
  • Patent number: 10316083
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: June 11, 2019
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Kathrin S. Michelsen, Stephan R. Targan
  • Patent number: 10301391
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: May 28, 2019
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • Patent number: 10294300
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: May 21, 2019
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
  • Patent number: 10294304
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: May 21, 2019
    Assignee: Pfizer Inc.
    Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
  • Patent number: 10288623
    Abstract: Disclosed are methods for diagnosing, staging, and predicting risk for developing rheumatoid arthritis and other inflammatory diseases, and methods for identifying treatment responders and non-responders.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: May 14, 2019
    Assignee: SINGULEX, INC.
    Inventors: John Allan Todd, Quynh Anh Thuc Lu, Sara Jane Le
  • Patent number: 10272138
    Abstract: The invention provides compositions and methods for treating inflammatory diseases, such as cardiac or hepatic inflammatory diseases, involving the use of parasite-derived neurotrophic factor (PDNF), or fragment of PDNF.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: April 30, 2019
    Assignee: TUFTS UNIVERSITY
    Inventor: Mercio A. Perrin
  • Patent number: 10273284
    Abstract: The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: April 30, 2019
    Assignee: East Carolina University
    Inventor: Mark D. Mannie
  • Patent number: 10274481
    Abstract: The present invention relates to use of inhibitors of Notch signalling pathway selected from the group consisting of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), its derivatives, in treating and/or preventing cancers.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: April 30, 2019
    Assignee: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
    Inventors: Freddy Radtke, Rajwinder Lehal, Viktoria Reinmüller, Jieping Zhu
  • Patent number: 10273286
    Abstract: The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: April 30, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, John O'Loughlin, Bernice Yeung, Yihong Zhang
  • Patent number: 10266602
    Abstract: The present invention relates to methods of treating liver cancer using a Notch signaling inhibitor. Compositions and methods for the treatment of liver cancers are also provided.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 23, 2019
    Assignee: Genentech, Inc.
    Inventors: Dorothy French, Erik Huntzicker, Christian W. Siebel
  • Patent number: 10265390
    Abstract: The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: April 23, 2019
    Assignee: CLEVELAND BIOLABS, INC.
    Inventors: Anatoli Gleiberman, Lyudmila Burdelya, Andrei Gudkov
  • Patent number: 10265407
    Abstract: Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: April 23, 2019
    Assignee: Yale University
    Inventors: Ira S. Mellman, Tarek M. Fahmy, William Mark Saltzman, Michael J. Caplan
  • Patent number: 10259869
    Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: April 16, 2019
    Assignees: MORPHOSYS AG, GALAPAGOS NV
    Inventors: Jan Dominik Haas, Jürgen Klattig, Nick Ernest René Vandeghinste
  • Patent number: 10251934
    Abstract: SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: April 9, 2019
    Assignee: Orbsen Therapeutics Limited
    Inventor: Stephen Joseph Elliman
  • Patent number: 10253105
    Abstract: The present application provides a bispecific antibody for preventing or treating an immune inflammatory disease by acting on both human TLR2 and human TLR4 to inhibit human TLR2- and human TLR4-mediated immune inflammatory effects. More specifically, the provided bispecific antibody is a bispecific antibody for human TLR2 and human TLR4, including a heavy chain variable region of an anti-human TLR2 antibody consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 4; a light chain variable region of an anti-human TLR2 antibody consisting of the amino acid sequence of amino acid numbers 1 to 113 of SEQ ID NO: 6; a heavy chain variable region of an anti-human TLR4 antibody consisting of the amino acid sequence of amino acid numbers 491 to 609 of SEQ ID NO: 4; and a light chain variable region of an anti-human TLR4 antibody consisting of the amino acid sequence of amino acid numbers 625 to 732 of SEQ ID NO: 4.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: April 9, 2019
    Assignee: Astellas Pharma Inc.
    Inventors: Satoshi Takeuchi, Masahito Sato, Jotarou Suzuki, Shinji Soga, Jun Takasaki, Koji Aoyama, Chie Okuyama
  • Patent number: 10246502
    Abstract: The application relates to a conjugate comprising interleukin-22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such conjugates in the treatment of a disease/disorder, such as autoimmune diseases, including inflammatory bowel disease (IBD).
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: April 2, 2019
    Assignee: Philogen S.P.A.
    Inventors: Franziska Sophie Bootz, Dario Neri